Navigating Chronic Kidney Disease Management: A New Era of therapeutic Strategies
Chronic kidney disease (CKD) represents a significant global health challenge,impacting millions adn demanding continuous refinement of treatment approaches. Over the last ten years, the landscape of CKD management has been dramatically reshaped by the arrival of sodium-glucose cotransporter-2 (SGLT2) inhibitors and, more recently, the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone. As of November 25, 2025, current clinical practice guidelines now advocate for angiotensin pathway inhibitors and SGLT2 inhibitors as the cornerstone of treatment for CKD characterized by proteinuria. Non-steroidal MRAs are then recommended as supplementary therapy for individuals with type 2 diabetes who continue to exhibit albuminuria despite initial interventions. Despite these advancements, a substantial proportion of patients still experience ongoing kidney function decline, notably those with persistent albuminuria, highlighting the need for further innovation.
| Therapeutic Class | Mechanism of Action | Key Benefit in CKD |
|---|---|---|
| Angiotensin Pathway Inhibitors | Block the renin-angiotensin-aldosterone system (RAAS) | Reduce proteinuria and slow CKD progression |
| SGLT2 Inhibitors | Reduce glucose reabsorption in the kidneys | Cardiorenal protection,slow CKD progression,reduce hospitalization for heart failure |
| Non-Steroidal MRAs (e.g., Finerenone) | Selectively block the mineralocorticoid receptor | Reduce albuminuria and slow CKD progression, particularly in diabetic patients |
The Evolution of CKD Treatment: From RAAS Blockade to Targeted Therapies
For decades, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (arbs) formed the bedrock of CKD management, primarily focused on mitigating proteinuria and slowing disease progression by modulating the renin-angiotensin-aldosterone system (RAAS). However, the introduction of SGLT2 inhibitors marked a paradigm shift.Initially developed for type 2 diabetes, these agents demonstrated remarkable cardiorenal benefits, extending beyond glycemic control. Landmark trials, such as EMPA-REG OUTCOME and CREDENCE, revealed that SGLT2 inhibitors significantly reduced the risk of cardiovascular events, hospitalization for heart failure, and slowed the decline in estimated glomerular filtration rate (eGFR) in patients with CKD, even in those without diabetes.
SGLT2 inhibitors with an eGFR ≥20 mL/min/1.73 m2 should be considered in people with T2D and CKD to reduce the risk of CKD progression, cardiovascular events, or both.
This revelation prompted a re-evaluation of treatment strategies, leading to the integration of SGLT2 inhibitors into mainstream CKD guidelines. A recent meta-analysis published in The Lancet (November 2025) confirmed a 25% reduction in CKD progression events with SGLT2 inhibitor use, reinforcing their pivotal role.
Addressing Residual Risk: The Role of Non-Steroidal mras
Despite the benefits conferred by RAAS blockade and SGLT2 inhibitors, a significant proportion of patients, particularly those with type 2 diabetes and persistent albuminuria, continue to experience CKD progression. This residual risk prompted the development and examination of non-steroidal MRAs like finerenone. Traditional MRAs, such as spironolactone and eplerenone, are associated with hyperkalemia and gynecomastia, limiting their widespread use. Finerenone, though, exhibits greater selectivity for the mineralocorticoid receptor in the kidney, minimizing these adverse effects.
The FIDELIO-DKD trial demonstrated that finerenone significantly reduced the risk of kidney failure and cardiovascular events in patients with type 2 diabetes, albuminuria, and CKD. Current guidelines, therefore, recommend finerenone as an adjunct to RAAS blockade and SGLT2 inhibitors